Thomas I. H. Dubin
Independent External DirectorDr. Thomas I. H. Dubin, also known as Tom, JD, MPH, serves as Executive Chairman of Cellphire, Inc. since April 2021. He is External Director at Notable Labs, Inc. since October 16, 2023.He serves as Independent Director at Intensity Therapeutics, Inc. since May 14,2024. He served as the Chief Legal Officer at Alexion Pharmaceuticals, Inc. since January 2010 to 2013 and served as its Senior Vice President since August 2005. Dr. Dubin served as General Counsel of Alexion Pharmaceuticals Inc. since January 2001 and served as its Vice President from January 2001 to July 2005. Before Alexion, Tom served as Vice President and General Counsel of ChiRex, Inc., an international corporation providing advanced process development services and specialty manufacturing to the pharmaceutical industry. He served as Vice President, General Counsel and Secretary of Rhodia Pharma Solutions, Inc., from February 1999 to September 2000. He held various positions with Warner-Lambert Company, including Assistant General Counsel, Pharmaceuticals from 1992 to 1999. Prior to his tenure with Warner-Lambert from 1987 to 1992, he was an attorney for five years at the law firm of Cravath, Swaine & Moore. He served as a Director of Bio Blast Pharma Ltd. since September 16, 2015 until 2018. He has been a Director at Bioblast Pharma Ltd. since September 16, 2015. He is Chair of Cellphire Therapeutics, a Director of Notable Laboratories, past Director of BioBlast Pharmaceuticals, member of the advisory board of Mythic Pharmaceuticals, Director of Norwalk Hospital and a member of Yale School of Public Health's Leadership Council. Dr. Dubin earned his B.A., cum laude, from Amherst College in 1984, M.P.H. from Yale University School of Public Health and his J.D. from New York University in 1987.
Positions
- Company NameNotable Labs, Ltd.Stock CodeNTBLQPositionIndependent External DirectorColleagues
- SAScott Alan McPhersonChief Financial Officer
- TPTuomo PatsiIndependent Chairman
- JPJoseph P. WagnerChief Scientific Officer
- KZKaile ZaggerInterim CEO & Chief Restructuring Officer
- GCGlenn C. MichelsonChief Medical Officer
- TGThomas GraneyIndependent External Director
- PFPeter FeinbergIndependent Director
- MGMichele GalenIndependent Director
